A multicenter phase II trial (the CHRONOS trial) of anti-EGFR rechallenge therapy with panitumumab guided by monitoring of the mutational status of RAS, BRAF, and EGFR in circulating tumor DNA (ctDNA). Here, EGFR is linked to neoplasm.